On January 26, 2021, Psyence Group Inc. (“Psyence”) (CSE: PSYG) announced that its common shares would begin trading on the Canadian Securities Exchange. Psyence listed after completing a reverse take-over (“RTO”) transaction with MindHealth Biomed Inc. In connection with the RTO, MindHealth BioMed Corp. completed a series of non-brokered common share and subscription receipt private placements raising a total of CAD$9,302,881.
Psyence was represented in its listing, and MindHealth was represented in the RTO and the private placement financings, by WeirFoulds LLP, with a team consisting of Rob Eberschlag (securities), Alvin Yau (securities), Dan Thomson (corporate), Ryan Morris (tax) and Dana Kriszenfeld (articling student).
Psyence intends to be a global platform for innovation, leading the way in naturally derived psychedelic therapies and the development and commercialization of related technologies and products.
WeirFoulds is pleased to have assisted Psyence and MindHealth with these transactions.
To learn more about our Securities Practice Group or Financial Services Practice Group or to contact one of our securities or financial services lawyers, visit our securities and banking and financial services overview pages.
